echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Poinsettia subsidiary obtains the registration certificate of Levocetirizine Hydrochloride Oral Drops

    Poinsettia subsidiary obtains the registration certificate of Levocetirizine Hydrochloride Oral Drops

    • Last Update: 2021-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 26, Poinsettia issued an announcement stating that its wholly-owned subsidiary Guangzhou Poinsettia Pharmaceutical Co.


    Levocetirizine hydrochloride oral drops are used to treat allergy-related symptoms of the following diseases, allergic rhinitis (including seasonal persistent allergic rhinitis and perennial persistent allergic rhinitis) and chronic idiopathic urticaria.


    Levocetirizine hydrochloride, as a third-generation antihistamine, has antihistamine and anti-inflammatory dual anti-allergic effects.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.